The Cancer BioChip System: a functional genomic assay for anchorage-independent three-dimensional breast cancer cell growth.
Advances in genomic research have revealed that each patient has their own unique tumor profile. While silencing RNA (siRNA) screening tests can identify which genes drive tumor cell growth, results obtained from these assays have been limited in their clinical translatability because they employ cell lines growing on flat surfaces. The Cancer BioChip System (CBCS) is a functional screening assay for identification of siRNA capable of inhibiting anchorage-independent three-dimensional (3D) cancer cell growth. Anchorage-independent growth assays are important in vitro predicators of regulators of cancer cell growth. Unique features of the CBCS include a Cancer BioChip, wherein cells incorporate different siRNAs in parallel and grow in a 3D matrix to form colonies that can be quantified using real-time imaging and an image analysis software. Thus, the CBCS can be developed as a tool for personalized identification of targeted cancer therapies.
Falcon Genomics, Inc., 160 North Craig Street, Suite 222, Pittsburgh, PA 15213, USA. rabbud@falcongenomics.com
Rula A
RA
Abbud-Antaki
Joie N
JN
Marhefka
Aimee L
AL
DeLuca
Michael P
MP
Zuromskis
D000818:Animals; D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D002448:Cell Adhesion / Q000235:genetics; D048708:Cell Growth Processes / Q000235:genetics; D045744:Cell Line, Tumor; D005260:Female; D023281:Genomics / Q000295:instrumentation / Q000379:methods*; D006801:Humans; D061986:MCF-7 Cells; D051379:Mice; D041681:NIH 3T3 Cells; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000235:genetics; D014162:Transfection / Q000295:instrumentation / Q000379:methods
D034741:RNA, Small Interfering